However, researchers did find that neurological dysfunction as a secondary outcome was more commonly seen in patients who had received cefepime.
“Patients in the cefepime group experienced fewer days alive and free of delirium and coma within 14 days than those in the piperacillin-tazobactam group,” the University of Minnesota’s Center for Infectious Disease Research and Policy wrote of the study.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.